REGISTER
Durvalumab Gains Seventh China Indication
AstraZeneca’s durvalumab has been approved in China in combination with carboplatin and paclitaxel followed by monotherapy maintenance for first-line treatment of dMMR primary advanced or recurrent endometrial cancer. The decision was supported by subgroup analyses from the Phase III DUO-E study and showed a 58% reduction in the risk of progression or death.

On January 22, AstraZeneca announced that Imfinzi, the brand name for durvalumab, had been approved by the NMPA in combination with carboplatin and paclitaxel for first-line treatment of adult patients with mismatch repair-deficient (dMMR) primary advanced or recurrent endometrial cancer, followed by maintenance treatment with durvalumab monotherapy.

This new domestic approval was supported by the prespecified subgroup analysis by mismatch repair status from the Phase III DUO-E trial, and the results have been published in the Journal of Clinical Oncology.

The DUO-E study (GOG 3041/ENGOT-EN10) was a three-arm, randomized, double-blind, placebo-controlled, multicenter Phase III trial. It evaluated first-line durvalumab plus platinum-based chemotherapy with carboplatin and paclitaxel, followed by maintenance with either durvalumab alone or durvalumab plus olaparib, compared with platinum-based chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer.

The dual primary endpoints of the trial were PFS for each treatment group versus standard therapy. Key secondary endpoints included overall survival, safety, and tolerability. Overall survival for durvalumab monotherapy maintenance and durvalumab plus olaparib maintenance continued to be assessed in the overall trial population.

In the study, compared with carboplatin plus paclitaxel, durvalumab plus carboplatin and paclitaxel followed by durvalumab monotherapy maintenance reduced the risk of disease progression or death by 58% in patients with dMMR endometrial cancer (HR=0.42). Median PFS was not reached in the durvalumab group, compared with 7.0 months in the control group.

In terms of safety, the overall safety and tolerability of durvalumab plus chemotherapy were favorable and broadly consistent with previous clinical trial findings, with no new safety signals observed.

Durvalumab is a human monoclonal antibody against PD-L1. By blocking the binding of PD-L1 to PD-1 and CD80, it interferes with tumor immune-evasion strategies and restores suppressed immune responses. To date, the drug has received 10 approved indications in the United States, 11 in the European Union, and seven in China.

0
0
Loading